Aaron Viray, MD
Pulmonary Disease · Reno, NVNPI 1851683130
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $793 and has fallen 67.3% since, to $259 in 2025. That places this record below the midpoint for pulmonary disease clinicians in NV, where the typical reported total is $1,728.
Across 63 payments — averaging $33.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$420
- Intuitive Surgical$193
- Actelion Pharmaceuticals US, Inc.$159
- Boehringer Ingelheim$146
- Johnson & Johnson$126
- AbbVie$124
- plus $958 from 19 others
What the payments were for
- Food & beverage$2,10999%
- Education$161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 18 | $420 |
| Intuitive Surgical | 2 | $193 |
| Actelion Pharmaceuticals US, Inc. | 3 | $159 |
| Boehringer Ingelheim | 4 | $146 |
| Johnson & Johnson | 7 | $126 |
| AbbVie | 1 | $124 |
| Ceribell, Inc. | 1 | $115 |
| Inspire Medical Systems, Inc. | 1 | $105 |
| Medtronic | 1 | $90 |
| EKOS Corporation | 1 | $86 |
| Veran Medical Technologies, Inc. | 1 | $76 |
| Genentech, Inc. | 1 | $75 |
| Amgen | 3 | $71 |
| Pfizer | 3 | $64 |
| Genentech USA, Inc. | 4 | $54 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Advanced Respiratory, Inc | 2 | $26 |
| Baxter Healthcare | 2 | $25 |
| Tactile Systems Technology Inc | 1 | $25 |
| United Therapeutics Corporation | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Pulmonx Corporation | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $19 |
| Insmed, Inc. | 1 | $16 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$124
- OPSUMIT$124
- TEFLARO$124
- Ceribell Rapid Response EEG$115
- NUCALA$115
- Da Vinci Surgical System$109
- Inspire$105
How this compares
$2,125 in reported general payments places this provider in the 50th percentile of 84 pulmonary disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 345 | $265,173 |
| Breo ElliptaFluticasone/Vilanterol | 109 | $45,150 |
| Spiriva RespimatTiotropium Bromide | 50 | $32,931 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 60 | $30,109 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 50 | $30,030 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $21,818 |
| SymbicortBudesonide/Formoterol Fumarate | 76 | $20,308 |
| Arnuity ElliptaFluticasone Furoate | 44 | $11,913 |
| Spiriva HandihalerTiotropium Bromide | 15 | $8,806 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 187 | $5,519 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $3,316 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $2,784 |
| Montelukast Sodium | 48 | $870 |
| Prednisone | 65 | $288 |
| Azithromycin | 36 | $260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $420 | $352,344558 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $146 | $62,961100 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 84 pulmonary disease providers in Nevada.
Other pulmonary disease in Reno
- Charles StahlmannReno$263K
- William GrahamReno$21K
- Amanda MorganReno$20K
- Steve MashourReno$12K
- Julia ChristopherReno$8K
- Christina SzotReno$7K
- Aleem SuraniReno$2K
- Hafiz MahboobReno$2K
- Kunwardeep DhillonReno$2K
- Shibu SkariaReno$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.